BCR::ABL1 kinetics for patients with suboptimal response at 12 and 18 months. There were 9 assessable patients who did not achieve MMR by 12 months, of whom 5 had ≥6 months additional follow-up. (A, dashed lines) Two patients (with BCR::ABL1 of 0.16% and 0.13% at 12 months) remained on asciminib 80 mg once a day (QD) and subsequently achieved MMR. (A) Three patients doubled their dose to asciminib 80 mg twice daily (BID), of whom 1 subsequently achieved MMR. There were 23 assessable patients who did not achieve MR4 by 18 months, of whom 11 had ≥6 months additional follow-up. (B, dashed lines) Four patients who remained on asciminib 80 mg once a day had a median fall of 0.08 log in the BCR::ABL1 qRT-PCR in the subsequent 6 months. (C) The 7 patients who doubled their asciminib dose to 80 mg twice daily had a median BCR::ABL1 drop of 0.22 log in the subsequent 6 months.